Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Canaccord Genuity Drug and Device Conference 2026
19 slides from Amplia Therapeutics's conference presentation, Oct 13, 2026
Slide 1: ASX Release: Amplia presents at CG Drug and Device Conference 2026
13 OCTOBER 2026 For personal use only ASX RELEASE AMPLIA PRESENTS AT CG DRUG AND DEVICE CONFERENCE 2026 Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), is pleased to release CEO and Managing Director Dr Chris Burns’ presentation to the Canaccord Genuity Drug and Device conf
Slide 2: ASX release continuation: narmafotinib trials
to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib wi
Slide 3: Narmafotinib – Pancreatic Cancer and Beyond
NARMAFOTINIB – al use only PANCREATIC CANCER AND BEYOND October 2026 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 1
Slide 4: Disclaimer
2 Disclaimer This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN Forward-looking statements are based on the Company’s good faith assumptions as to the financial 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 Jun 202
Slide 5: Amplia Therapeutics: Improving treatment options for hard-to-treat cancers
3 Amplia Therapeutics Improving treatment options for hard-to-treat cancers Listed biotech company (ASX:ATX; OTCQB:INNMF) developing narmafotinib: a FAK inhibitor that decreases fibrosis and reverses adaptive resistance limiting new and existing cancer therapies; al use only currently in Phase 2 for
Slide 6: The FAK Opportunity
4 The FAK Opportunity A large and unmet clinical need exists in cancers where FAK contributes to disease Lead program al use only Pancreatic Cancer Ovarian Cancer kRAS Combinations US$32b lung cancer market3 US$2.5b market1 US$3.9b market2 US$19b CRC market4 Exciting data from ACCENT Trial PRROSE Tr
Slide 7: ACCENT Pancreatic Cancer Trial
5 ACCENT Pancreatic Cancer Trial Phase 1b/2a clinical trial in Australia and South Korea al use only Narmafotinib plus standard-of-care Narmafotinib Chemotherapy chemotherapy Newly diagnosed patients Metastatic disease Taken orally in 64 patients at top dose narmafotinib days preceding Three infusio
Slide 8: ACCENT Pancreatic Cancer Trial
6 ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / Abraxane in first-line advanced pancreatic cancer al use only 7.8% 70% 11.1 months month No Extra Burden s Complete Disease Median Safety & response rate control rate overall survival tolerability Superior to chemo alone Chemo alone - Che
Slide 9: ACCENT registration pathway
7 ACCENT registration pathway A three-part registration pathway designed around FDA feedback Underway Final planning Final planning ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 al use only Daily dosing at two dose levels Builds on ACCENT Mini data to Pivotal registrational study • Gemcitabine + Abra
Slide 10: Combinations with kRAS inhibitors
al use only Combinations with kRAS inhibitors FAK inhibition offers significant benefit 5
Slide 11: kRAS mutations prevalent in cancer
9 kRAS mutations prevalent in cancer Significant cancer driver in multiple indications Clinical studies demonstrating al use only good activity 80+ kRAS drugs now in clinical development • Biotech and Pharma • Across pancreatic cancer, NSCLC, colorectal cancer and others Resistance and tolerability
Slide 12: The Opportunity Ahead
10 The Opportunity Ahead Combinations critical to development strategy al use only
Slide 13: Narmafotinib target processes leading to resistance
11 Narmafotinib target processes leading to resistance Narmafotinib breaks down fibrosis surrounding the tumour, improves immune infitrate and blocks survival and resistance pathways in cancer cells al use only kRAS inhibitor kills most cells Resistance Cancer cells Cancer cells in tumour regrow
Slide 14: Narmafotinib target processes leading to resistance
12 Narmafotinib target processes leading to resistance Narmafotinib breaks down fibrosis surrounding the tumour, improves immune infitrate and blocks survival and resistance pathways in cancer cells Narmafotinib al use only kRAS inhibitor kills most cells Resistance Cancer cells Dead cancer in tumou
Slide 15: Lilly Collaboration
13 Lilly Collaboration Enhancing efficacy of next-generation G12C inhibitor Previously treated KRAS G12C-mutant advanced or Phase 1b metastatic NSCLC al use only Olomorasib (100 mg, BID) Phase 1b/2b study Narmafotinib Narmafotinib Narmafotinib (200 mg, QD) (400 mg, QD) (600 mg, QD) • Dose escalation
Slide 16: Estimated Development Timeline
Estimated Development Timeline 14 2026 2027 2028 2029 ACCENT al use only ACCENT-mini safety data ACCENT-reg FDA Meeting FDA Meeting Olomorasib combination PRROSE CONFIDENTIAL
Slide 17: Forthcoming Catalysts
15 Forthcoming Catalysts al use only Timing Milestone Q4 2026 FDA Meeting discussing development Q4 2026 First patient dosed ACCENT-mini Q4 2026 First patient dosed PRROSE Q4 2026 Ethics submission Lilly trial Q1 2027 ACCENT-mini key data available Q1 2027 First patient dosed Lilly trial Q2 2027 FDA
Slide 18: Board and Management
16 Board and Management World-class expertise SENIOR MANAGEMENT BOARD Rhiannon Jones PhD GAICD al use only COO Jason Lickliter MBBS FRACP CMO Jane Bell AM Warwick Tong Robert Peach Brett Carter Chris Burns LLB LLM (Lond) FAICD MB ChB MP P GAICD P hD BS c MBA GAICD P hD GAICD FAHMS Chair Director Dir
Slide 19: Chris Burns, CEO and MD contact
al use only Chris Burns CEO and MD chris@ampliatx.com Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF info@ampliatx.com ampliatx.com
Amplia Therapeutics — Canaccord Genuity Drug and Device Conference 2026 on 6ix